DSPACE
25.1.2023 15:55:40 CET | Business Wire | Press release
On April 17, 2023, Dr. Carsten Hoff (49) will become the new CEO of the dSPACE group succeeding Martin Goetzeler (60), who is leaving his post at his own request and for personal reasons. To ensure a smooth handover, Martin Goetzeler will continue to be available to the new CEO in an advisory capacity after April 17, 2023.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230125005072/en/
From left to right, dSPACE founder and shareholder Dr. Herbert Hanselmann, Dr. Carsten Hoff and Martin Goetzeler. (Photo: Business Wire)
Dr. Carsten Hoff is a highly experienced manager, who is ideally suited to the tasks ahead at dSPACE. He comes from a research and development-centric background with a degree in electrical engineering and a doctorate in computer science. He has international management experience and is familiar with dSPACE and the company's products.
Dr. Carsten Hoff is currently Managing Director of CLAAS E-Systems. Prior to that, he worked in various management positions at the automotive supplier HELLA. He will use his extensive experience from previous positions to provide strategic impetus for dSPACE and to continue to drive forward the new topics of software-based simulation and validation.
"I am very pleased to be joining the dSPACE company. I am very impressed by the company's development and dSPACE's role in the automotive industry. The values that the family-owned company dSPACE stands for convinced me,” stated Dr. Carsten Hoff.
"Dr. Carsten Hoff, an internationally experienced and technically skilled manager who is very familiar with the current challenges in our target markets is taking the helm – I wish him a good start in the company and with our customers," said Dr. Herbert Hanselmann, founder and shareholder of dSPACE.
"Under Martin Goetzeler's successful leadership, dSPACE has sustainably strengthened its market position by setting a decisive course in terms of consistent portfolio expansion, globalization, and future-oriented structures. By continually expanding future investments and the team, he has succeeded in continuing the great growth rate at a high level of sales in challenging years," said Dr. Herbert Hanselmann, adding, "We regret but respect Martin Goetzeler's decision. I would like to expressly thank him for his important contribution, his extraordinary commitment, and the close cooperation based on trust."
"It has been an exciting five years. The excellent and close cooperation with the entire dSPACE team, our customers and partners, and the shareholder family was the key to success and motivation at all times. I would like to thank everyone very much for this," said Martin Goetzeler. "After a fulfilling professional career, I would like to devote more time to my personal and family tasks and interests in the future. I wish my successor and all dSPACE employees the necessary skills, much success, and all the best for the future," said Goetzeler.
Martin Goetzeler has led the dSPACE company since March 1, 2018. Portfolio expansions in virtual and real simulation and validation to cover market and customer requirements in a timely manner, especially in automated and autonomous driving and in the software-defined vehicle were important milestones during this time. In addition to the great importance of software-in-the-loop simulation in this process, technologies such as AI and cloud are now also being used in the products. At the same time, he systematically built up structures and processes to sustainably secure the strong global growth.
About dSPACE
dSPACE is a leading provider of simulation and validation solutions worldwide for developing networked, autonomous, and electrically powered vehicles. The company's range of end-to-end solutions are used particularly by automotive manufacturers and their suppliers to test the software and hardware components in their new vehicles long before a new model is allowed on the road. Not only is dSPACE a sought-after partner in vehicle development, engineers also rely on our know-how at dSPACE when it comes to aerospace and industrial automation. Our portfolio ranges from end-to-end solutions for simulation and validation to engineering and consulting services as well as training and support. With approximately 2,200 employees worldwide, dSPACE is headquartered in Paderborn, Germany, has three project centers in Germany, and serves customers through regional dSPACE companies in the USA, the UK, France, Japan, China, Croatia, and South Korea.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230125005072/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Buys Back Shares Worth CHF 232 Million in the Context of Accelerated Bookbuild Offering11.3.2026 07:00:00 CET | Press release
Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that it has agreed to repurchase 1.6 million shares at a price of CHF 143.75 per share for a total consideration of CHF 232 million in the context of the accelerated bookbuild offering (“ABO”) of Galderma shares by Sunshine SwissCo GmbH (“EQT”), Abu Dhabi Investment Authority (Private Equities Department) and Auba Investment Pte. Ltd. (all together the “Selling Shareholders”) launched yesterday evening. The repurchase was made at the same price per share determined by the bookbuilding offering. As a result of yesterday evening’s ABO, the Selling Shareholders have fully divested their remaining stake in Galderma. The repurchase, which is expected to settle on March 13 is being financed by Galderma’s existing liquidity on hand and will not affect the company’s ability to deliver on its strategic and financing priorities. The shares will be held in treasury for futur
Thales Launches SkyDefender: The Integral Air and Missile Defence Dome With Artificial Intelligence11.3.2026 07:00:00 CET | Press release
SkyDefender is a multi-layer, multi-domain Integrated Air and Missile Defence system providing full protection against all types of air threats, on land, at sea and in space. SkyDefender integrates a network of advanced sensors and effectors with a versatile command and control (C2) system. With its open and modular architecture, it is fully compatible with existing air defence systems. Combining Thales’ expertise in cybersecurity and advanced artificial intelligence through cortAIx, Thales AI accelerator, SkyDefender enables operational superiority and proactive defence against cyberattacks and evolving threats. Thales is capable of delivering this critical protection globally from today. As air and missile threats are evolving faster than ever, from slow-moving drones to hypersonic missiles, attacks are becoming increasingly complex, saturating and unpredictable. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260310398606/
Curatis and Neupharma Announce Exclusive Licensing Agreement to Develop and Market Corticorelin (C-PTBE-01) for the Treatment of Peritumoral Brain Edema in Japan11.3.2026 07:00:00 CET | Press release
Japan is one of the world's most important pharmaceutical markets after the US and Europe. Neupharma’s team has extensive experience in developing and successfully commercialising orphan drugs as well as speciality care medicines in Japan, including a blockbuster drug. The agreement with Neupharma includes upfront and milestone payments of up to CHF 83.5 million as well as royalties of up to 20% on sales. The population of available patients eligible for corticorelin treatment associated with peritumoral brain edema is estimated at 60,000 in Japan and 500,000 worldwide. Global market potential is forecasted to exceed USD 1 billion annually. Curatis Holding AG (SIX: CURN) and Neupharma Co., Ltd. (“Neupharma”), a Japanese pharmaceutical company specializing in oncology, immunology, pulmonology and cardiology disorders, today announce an exclusive license and development agreement for corticorelin (C-PTBE-01) in Japan. Under the terms of the agreement, Neupharma will receive exclusive rig
Galderma Completes Successful Placement of EUR 500 Million Eurobond11.3.2026 06:55:00 CET | Press release
Galderma Group AG (SWX:GALD): NOT FOR DISTRIBUTION IN THE UNITED STATES OR IN ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE RESTRICTED BY APPLICABLE LAW OR REGULATION. Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced the successful placement of a single-tranche EUR 500 million Eurobond. The bond has a 5-year maturity and carries a fixed-rate annual coupon of 3.375%. The Eurobond was placed on March 10, 2026, with settlement expected on March 17, 2026, and will be listed on the SIX Swiss Exchange. Citigroup, ING, J.P. Morgan and RBC Capital Markets jointly led the transaction. Net proceeds from the transaction will be used to fully repay Galderma’s existing bank term loan issued in connection with the company’s initial public offering in March 2024. The transaction represents the final step in Galderma’s refinancing process, having obtained two investment grade credit ratings. Galderma is currently rated ‘BBB’ (stable outlook) by Fitc
Estithmar Holding Net Profit Surges 122% to QAR 938 Million; Revenue Rises 54% to QAR 6.4 Billion for the Year Ended 31 December 202510.3.2026 22:52:00 CET | Press release
- Sustainable Growth Driven by International Expansion - Significant Increase Across Key Metrics Estithmar Holding Q.P.S.C. has announced its financial results for the year ended 31 December 2025. The group reported a 54% increase in revenue to QAR 6.4 billion, compared with QAR 4.2 billion in 2024. Gross profit rose to QAR 2.1 billion, up from QAR 1 billion in 2024, representing growth of 111%. EBITDA reached QAR 1.5 billion, an increase of 102% year-on-year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260310410214/en/ Estithmar Holding Net Profit Surges 122% to QAR 938 Million; Revenue Rises 54% to QAR 6.4 Billion for the Year Ended 31 December 2025 (Photo: AETOSWire) Net profit climbed 122% compared with 2024, reaching QAR 938 million. Earnings per share increased by 145% to QAR 0.264. The growth in net profit was primarily driven by higher revenues, particularly from the specialized contracting and healthcare sectors.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
